Advertisement

---

CEMPRA, INC.

Cempra Prices Public Offering of Common Stock

[2013-06-14] -


Cempra Announces Proposed Public Offering of Common Stock

[2013-06-13] -


Cempra Provides Guidance on the Clinical Program Required for Regulatory Approval for Solithromycin for Community-Acquired Bacterial Pneumonia (CABP)

[2013-06-13] - FDA Proposes Qualified Pathogen List that Includes Pathogens, such as Streptococcus pneumoniae, that are Susceptible to Solithromycin


Cempra, Inc., Announces Notification of Patent Allowance for U.S. Patent Application on Taksta Loading Dose Formulation

[2013-05-30] - Patent Protects U.S. Market Exclusivity to 2029 Excluding Possible Patent Term Extensions


Cempra, Inc. to Present at Jefferies 2013 Global Healthcare Conference

[2013-05-29] -


Cempra Awarded $58 Million Contract to Develop Antibiotic for Pediatric Use and Biodefense by Biomedical Advanced Research and Development Authority (BARDA)

[2013-05-28] - - Cempra to Host Conference Call and Webcast at 8:30 a.m. EDT, Tomorrow, May 29, 2013 -


Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)

[2013-05-20] - Solithromycin demonstrated enhanced anti-inflammatory response, in vitro
Data presented at the American Thoracic Society International Conference


Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan

[2013-05-13] - - Cempra to Host Conference Call and Webcast at 4:30 p.m. EDT, Today, May 13, 2013 -


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers